Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI
Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid...
Furkejuvvon:
Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Artigo |
Giella: | eaŋgalasgiella |
Almmustuhtton: |
2020
|
Liŋkkat: | https://doi.org/10.1148/radiol.2020192018 |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Lasit vuosttaš kommeantta. Visot kommeanttat leat almmolaččat.!